* Plus Therapeutics Inc is expected to show a rise in quarterly revenue when it reports results on October 29 (estimated) for the period ending September 30 2024

* The Austin Texas-based company is expected to report a 22.3% increase in revenue to $1.517 million from $1.24 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Plus Therapeutics Inc is for a loss of 56 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Plus Therapeutics Inc is 32.00​, above​ its last closing price of $1.35. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.46 -0.53 -0.56 Missed -5.7

Mar. 31 2024 -1.08 -1.09 -0.75 Beat 31.2

Dec. 31 2023 -0.83 -1.07 -0.84 Beat 21.7​

Jan. 1 0001 -1.02 -1.12 -1.00 Beat 10.9

​​Jun. -1.93 -1.90 -0.59 Beat 69.2

30 2023

Jan. 1 0001 -1.91 -1.90 -2.10 Missed -10.5​

Dec. 31 2022 -1.50 -1.80 -3.30 Missed -83.3

Sep. 30 2022 -3.02 -3.04 -2.85 Beat 6.2

This summary was machine generated October 27 at 14:51 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)